Advanced or Metastatic Gastric Cancer Clinical Trial
Official title:
A Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG003 in EGFR-Positive, HER2-Negative Advanced Gastric Cancer.
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally advanced or metastatic gastric cancer.
Approximately 6054 patients will be enrolled to evaluate the safety and preliminarily efficacy of MRG003. Patients will receive 2.0 mg/kg dose of MRG003 intravenously every 3 weeks (Q3W) and may receive up to 24 months of MRG003 if there is evidence of clinical benefit to the patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02650375 -
Study of Metatinib Tromethamine Tablet
|
Phase 1 | |
| Recruiting |
NCT04492488 -
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01512745 -
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
|
Phase 3 |